The Food and Drug Administration (FDA) has approved Jaypirca® (pirtobrutinib) for the treatment of adult patients with previously untreated chronic ...

Researchers evaluated the role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a potential treatment for obstructive sleep apnea in patients with obesity.

The Food and Drug Administration (FDA) has approved the Autus Size-Adjustable Valve (Edward Lifesciences) for pediatric patients with congenital heart ...

Tasimelteon significantly advanced sleep onset by 42.5 minutes in adults with delayed sleep-wake phase disorder, according to topline phase 3 data.

Chronic pain was most common patient-reported qualifying condition, accounting for 64.5 and 31.9% in 2016 and 2024.

The effect of semaglutide on major adverse cardiovascular events (MACE) is only partially due to known risk factors, according to a study published online September 23 in the European Heart Journal.

Polypharmacy involving prescription medications affected more than one-third of older adults in 2021 to 2023, according to a ...

Supported by phase 3 FENhance 1, FENhance 2, and FENtrepid trial results, oral fenebrutinib reduced relapse rates and showed numerical benefits in delaying disability progression across the MS ...

Phase 3 trial data show that zalunfiban administered on first medical contact significantly improved preprocedural coronary flow and 30-day clinical outcomes in STEMI.

Findings show reductions in inappropriate medication, medication underuse and overuse, and missing vaccinations ...

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

The expanded indication for mavacamten offers a novel targeted medical therapy for pediatric patients aged 12 years and older with symptomatic oHCM, backed by data from the phase 3 SCOUT-HCM trial.